Literature DB >> 15584032

Interrater agreement in the assessment of motor manifestations of Huntington's disease.

Penelope Hogarth1, Elise Kayson, Karl Kieburtz, Karen Marder, David Oakes, Diana Rosas, Ira Shoulson, Nancy S Wexler, Anne B Young, Hongwei Zhao.   

Abstract

With prospects improving for experimental therapeutics aimed at postponing the onset of illness in preclinical carriers of the Huntington's disease (HD) gene, we assessed agreement among experienced clinicians with respect to the motor manifestations of HD, a relevant outcome measure for preventive trials in this population. Seventy-five clinicians experienced in the evaluation of patients with early HD and six non-clinicians were shown a videotape compiled from the film archives of the United States-Venezuela Collaborative HD Research Project. Observers were asked to rate a 2-3-minute segment of the motor examination for each of 17 at-risk subjects. The rating scale ranged from 0 (normal) to 4 (unequivocal extrapyramidal movement disorder characteristic of HD). As measured by a weighted kappa statistic, there was substantial agreement among the 75 clinicians in the judgment of unequivocal motor abnormalities comparing scale ratings of 4 with ratings that were not 4 (weighted kappa = 0.67; standard error (SE) = 0.09). Agreement among the non-clinicians was only fair (weighted kappa = 0.28; SE = 0.10). Even under the artificial conditions of a videotape study, experienced clinicians show substantial agreement about the signs that constitute the motor manifestations of illness in subjects at risk for HD. We expect these findings to translate to a similar level of interobserver agreement in the clinical trial setting involving experienced investigators examining live patients. 2005 Movement Disorder Society.

Entities:  

Mesh:

Year:  2005        PMID: 15584032     DOI: 10.1002/mds.20332

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  23 in total

Review 1.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

2.  Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.

Authors:  Karen Marder; Yian Gu; Shirley Eberly; Caroline M Tanner; Nikolaos Scarmeas; David Oakes; Ira Shoulson
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

3.  Earliest functional declines in Huntington disease.

Authors:  Leigh J Beglinger; Justin J F O'Rourke; Chiachi Wang; Douglas R Langbehn; Kevin Duff; Jane S Paulsen
Journal:  Psychiatry Res       Date:  2010-05-15       Impact factor: 3.222

4.  Polysomnographic Findings and Clinical Correlates in Huntington Disease: A Cross-Sectional Cohort Study.

Authors:  Carla Piano; Anna Losurdo; Giacomo Della Marca; Marcella Solito; Giovanna Calandra-Buonaura; Federica Provini; Anna Rita Bentivoglio; Pietro Cortelli
Journal:  Sleep       Date:  2015-09-01       Impact factor: 5.849

Review 5.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

Review 6.  Huntington disease: natural history, biomarkers and prospects for therapeutics.

Authors:  Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi
Journal:  Nat Rev Neurol       Date:  2014-03-11       Impact factor: 42.937

7.  Time-varying proportional odds model for mega-analysis of clustered event times.

Authors:  Tanya P Garcia; Karen Marder; Yuanjia Wang
Journal:  Biostatistics       Date:  2019-01-01       Impact factor: 5.899

8.  HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).

Authors:  N E Carlozzi; S G Schilling; J-S Lai; J S Paulsen; E A Hahn; J S Perlmutter; C A Ross; N R Downing; A L Kratz; M K McCormack; M A Nance; K A Quaid; J C Stout; R C Gershon; R E Ready; J A Miner; S K Barton; S L Perlman; S M Rao; S Frank; I Shoulson; H Marin; M D Geschwind; P Dayalu; S M Goodnight; D Cella
Journal:  Qual Life Res       Date:  2016-08-13       Impact factor: 4.147

9.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

10.  Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status.

Authors:  Leigh J Beglinger; Kevin Duff; Jessica Allison; Danielle Theriault; Justin J F O'Rourke; Anne Leserman; Jane S Paulsen
Journal:  J Clin Exp Neuropsychol       Date:  2009-10-29       Impact factor: 2.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.